QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

Compugen Stock Price, News & Analysis (NASDAQ:CGEN)

$0.78
+0.08 (+11.41%)
(As of 12/4/2023 ET)
Compare
Today's Range
$0.70
$0.85
50-Day Range
$0.53
$1.00
52-Week Range
$0.53
$1.49
Volume
450,320 shs
Average Volume
363,072 shs
Market Capitalization
$67.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33

Compugen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
966.5% Upside
$8.33 Price Target
Short Interest
Healthy
1.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.31) to ($0.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

585th out of 952 stocks

Biotechnology Industry

14th out of 33 stocks


CGEN stock logo

About Compugen Stock (NASDAQ:CGEN)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

CGEN Stock Price History

CGEN Stock News Headlines

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Compugen: Q3 Earnings Snapshot
Compugen Q3 2023 Earnings Preview
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
5 Analysts Have This to Say About Compugen
Compugen Reports Second Quarter 2023 Results
CGEN - Compugen Ltd.
See More Headlines
Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/26/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGEN
Employees
69
Year Founded
1993

Price Target and Rating

Average Stock Price Target
$8.33
High Stock Price Target
$13.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+941.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-33,690,000.00
Pretax Margin
-420.49%

Debt

Sales & Book Value

Annual Sales
$7.50 million
Book Value
$0.90 per share

Miscellaneous

Free Float
78,396,000
Market Cap
$69.30 million
Optionable
Optionable
Beta
2.52

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Anat Cohen-Dayag Ph.D. (Age 56)
    CEO, President & Director
    Comp: $796.52k
  • Dr. Zurit Levine Ph.D. (Age 55)
    Senior Vice President of Technology Innovation
    Comp: $345.7k
  • Dr. Henry Adewoye M.D. (Age 58)
    Senior VP & Chief Medical Officer
    Comp: $605.29k
  • Dr. Pierre Ferre Ph.D. (Age 46)
    Vice President of Preclinical Development
    Comp: $415.1k
  • Mr. Alberto Sessa (Age 61)
    Chief Financial Officer
  • Dr. Eran Ophir Ph.D. (Age 45)
    Chief Scientific Officer
  • Ms. Yvonne Naughton
    Head of Investor Relations & Corporate Communications
  • Mr. Eran Ben Dor
    General Counsel & Corporate Secretary
  • Ms. Dorit Amitay (Age 55)
    Vice President of Human Resources
  • Dr. Yaron Turpaz M.B.A. (Age 52)
    Ph.D., Senior VP & Senior Advisor of Data and Informatics Solutions














CGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Compugen stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CGEN shares.
View CGEN analyst ratings
or view top-rated stocks.

What is Compugen's stock price target for 2024?

5 Wall Street analysts have issued 1-year price objectives for Compugen's shares. Their CGEN share price targets range from $4.00 to $13.00. On average, they anticipate the company's stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 966.5% from the stock's current price.
View analysts price targets for CGEN
or view top-rated stocks among Wall Street analysts.

How have CGEN shares performed in 2023?

Compugen's stock was trading at $0.7157 at the beginning of 2023. Since then, CGEN stock has increased by 9.2% and is now trading at $0.7814.
View the best growth stocks for 2023 here
.

Are investors shorting Compugen?

Compugen saw a decline in short interest in November. As of November 15th, there was short interest totaling 1,350,000 shares, a decline of 10.6% from the October 31st total of 1,510,000 shares. Based on an average daily trading volume, of 174,600 shares, the short-interest ratio is presently 7.7 days. Currently, 1.6% of the company's shares are short sold.
View Compugen's Short Interest
.

When is Compugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our CGEN earnings forecast
.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.02.

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

Who are Compugen's major shareholders?

Compugen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Taylor Frigon Capital Management LLC (2.23%), Silverarc Capital Management LLC (0.40%), UBS Group AG (0.32%), Kingsview Wealth Management LLC (0.10%), Tocqueville Asset Management L.P. (0.09%) and Oppenheimer & Co. Inc. (0.04%).

How do I buy shares of Compugen?

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CGEN) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -